MA
ALDR

MUFG Americas’s Alder Biopharmaceuticals ALDR Stock Holding History

MUFG Americas’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,060
Closed -$13K – 1200
2017
Q3 		$13K Buy
+1,060
New +$11.1K ﹤0.01% 829

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

MUFG Americas's ALDR Position: Q4 2017 in Review

MUFG Americas sold out of Alder Biopharmaceuticals (ALDR) in Q4 2017, closing a stake of 1,060 shares — an estimated $13K sold.

MUFG Americas first reported a position in ALDR in Q3 2017 and held it in 1 quarter. The position peaked at $13K in Q3 2017. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

  • MUFG Americas reported no remaining Alder Biopharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • MUFG Americas sold 1,060 Alder Biopharmaceuticals shares in Q4 2017, an estimated $13K.
  • MUFG Americas first reported a position in Alder Biopharmaceuticals in Q3 2017 and held it in 1 quarter.
  • MUFG Americas's Alder Biopharmaceuticals position peaked at $13K in Q3 2017.
  • 140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on MUFG Americas's 13F filing for Q4 2017, filed 8 Feb 2018.